Findings from the StrateGIST 1 trial show that velzatinib (IDRX-42), a broad-spectrum oral therapy, demonstrates strong clinical activity across multiple lines of treatment in patients with advanced gastrointestinal stromal tumors (GIST). The drug is designed to overcome resistance driven by KIT gene mutations, which account for about 75% to 80% of GIST cases. While current therapies […]
Findings from the Phase 3 SARC041 trial show that abemaciclib (Verzenio) significantly delays disease progression in patients with advanced dedifferentiated liposarcoma (DD-LPS), a rare and aggressive soft-tissue cancer. The drug targets CDK4, a protein amplified in nearly all DD-LPS cases that drives tumor growth. By inhibiting this pathway, abemaciclib slows cancer progression more effectively than
SARC041 Trial Shows Abemaciclib Dramatically Delays Progression in Rare Liposarcoma Read More »
Results from a Phase 2a trial suggest that adding atebimetinib to modified gemcitabine and nab-paclitaxel (mGnP) chemotherapy may improve outcomes for patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). Atebimetinib is a novel MEK inhibitor designed with a short half-life, allowing it to temporarily block cancer-growth signaling while reducing the toxicities and resistance often seen
Results from the Phase 3 OptimUM-02 trial show that the combination of darovasertib and crizotinib significantly improves outcomes for patients with HLA-A*02:01–negative metastatic uveal melanoma, a rare and aggressive form of eye cancer with no approved treatment options for this population. The targeted therapy works by blocking the PKC signaling pathway, which is activated in more
The Phase 3 EMERALD-3 trial found that adding immunotherapy to standard treatment significantly delayed disease progression in patients with unresectable hepatocellular carcinoma (HCC) eligible for transarterial chemoembolization (TACE). The study enrolled 760 patients and compared STRIDE immunotherapy (tremelimumab plus durvalumab) combined with lenvatinib and TACE, STRIDE plus TACE, and TACE alone. Patients receiving the full combination
A small clinical trial led by researchers at the Dana-Farber Cancer Institute suggests that a vitamin D analog may help improve treatment outcomes in pancreatic cancer. The study tested paricalcitol, an FDA-approved drug used for kidney disease, in combination with standard chemotherapy for 36 patients with previously untreated metastatic pancreatic cancer. Researchers found that paricalcitol
Vitamin D Drug Shows Promise in Boosting Pancreatic Cancer Treatment Response Read More »
A clinical trial involving 500 patients has shown that the daily oral drug daraxonrasib may significantly extend survival in advanced pancreatic cancer, an outcome researchers are describing as a major breakthrough. In the study presented at the American Society of Clinical Oncology annual meeting, patients receiving daraxonrasib lived a median of 13.2 months, compared with
Daraxonrasib Doubles Survival in Advanced Pancreatic Cancer in Landmark Trial Read More »
The phase 3 BREAKWATER trial shows that a targeted combination of encorafenib (Braftovi), cetuximab (Erbitux), and FOLFIRI chemotherapy significantly improves outcomes for patients with previously untreated BRAF V600E–mutant metastatic colorectal cancer. The regimen is now considered a new standard of care following FDA traditional approval in February 2026. The study enrolled 147 patients and compared
ncorafenib Combination Becomes New Standard in BRAF V600E Metastatic Colorectal Cancer Read More »
Abemaciclib (Verzenio) has shown the first positive phase 3 trial result in advanced or metastatic dedifferentiated liposarcoma (DDLS), according to the SARC041 study. The oral CDK4/6 inhibitor significantly delayed disease progression compared with placebo in a cancer type with very limited treatment options. The trial enrolled 108 patients with progressive, recurrent, or metastatic DDLS randomized
Abemaciclib Becomes First Drug to Show Phase 3 Benefit in Advanced Liposarcoma Read More »
The phase 3 frontMIND trial has demonstrated that adding tafasitamab (Monjuvi) and lenalidomide (Revlimid) to standard R-CHOP chemotherapy improves outcomes for patients with newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL). After a median follow-up of 35.2 months, the combination reduced the risk of disease progression or death by 25% compared with R-CHOP alone. Two-year
frontMIND Trial Shows Tafasitamab Combination Improves Outcomes in High-Risk DLBCL Read More »